Venture Capital
Kintan Pty Ltd provides early stage support to a small portfolio of early stage technology companies. The support is generally provided as a combination of expertise and capital for specific activities, such as intellectual property protection, that helps establish a pathway to more substantial funding. Investments in the enterprises are held by Kintan or associated entities.
Kintan's current portfolio includes:
- Loke Goup Holdings Pty Ltd, an electronic payments and loyalty company;
- Havah Therapeutics, a biotechnology company developing a novel approach to breast cancer treatment;
- iRiccorgPharm Pty Ltd, a biotechnology company developing products that utilize natural, organic compounds as antibiotic alternatives for livestock;
- Neo Stem Cell Technologies (Group) Limited, a Hong Kong based stem cell banking and R&D company;
- Wellend Health, clinics providing a large market of women the opportunity reduce their risk of breast cancer;
- Cleantech Council, provides IP and investment into clean technology projects;
- CSF-1 patent portfolio, a portfolio of patents based on past and ongoing research into the use of CSF-1 to assist premature babies.
Kintan is not currently seeking additions to its portfolio.
Kintan is also an advisor to Sydney based venture capital company, Innovation Capital and to Singapore based venture capital company 5i Capital.
|
|
5i Capital is the first and only specialist cybersecurity venture capital manager licensed in Singapore and operating in Asia-Pacific. The 5i Cyber Fund One will invest in high potential early stage and start-up cybersecurity ventures in Asia Pacific (excluding China) with a key focus on Singapore, Australia & New Zealand. |
News :
Havah Therapeutics clinical trial information
Dr Stephen Birrell of Wellend Health on ABC Radio
Havah Therapeutics awarded significant US patent for reducing breast cancer risk
